Akorn (AKRX) is breaking out on the stock market today, boosted by a bullish initiation report. It could also be getting a lift from optimism for more buyouts in the industry: Pfizer (PFE) announced on Thursday that it’s buying injectable-drug maker Hospira (HSP) for $17 billion. Check out this video to get all the details about top-performing stock Akorn — it’s in buy range. Follow Alissa Williams on Twitter: @IBD_AWilliams.
With a top IBD Composite Rating of 99 and four straight quarters of accelerated EPS growth, generic drug maker Akorn (AKRX) is already doing pretty well. A new analyst report outlines even more reasons to be bullish on the stock for 2015. Lake Forest, Ill.-based Akorn makes diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs and injectable pharmaceuticals. Much of its attention this year has focused on a pair of high-profit
Salix Pharmaceuticals missed third-quarter earnings and sales forecasts and announced the sudden resignation of its chief financial officer, sending shares plunging late Thursday. Earlier, Akorn (AKRX) stock sold off on its messy Q3 results, but investors viewed its issues as mild, relatively, compared with its midsize pharma peer. Salix Pharmaceuticals (SLXP) reported after the close that earnings excluding one-time items rose 72%